Biossance's net profit in 2025 is 173 million yuan, a year-on-year increase of 416.37%

NightAirdropper · 2026-02-28T09:43:15+00:00

Biossance released its 2025 performance quick report, with operating revenue reaching 1.379 billion yuan, a year-on-year increase of 40.63%; net profit of 173 million yuan, a year-on-year increase of 416.37%. The company's performance growth is attributed to expansion in overseas markets and recovery in the domestic biopharmaceutical sector, while also strengthening R&D and lean management to improve profitability.

NightAirdropper

2026-02-28 09:43:15

Abstract generation in progress

Beijing Business Daily (Reporter Ding Ning) reported that on the evening of February 26, Baiao Sai Tu (688796) released its 2025 performance forecast, showing that the company achieved an operating revenue of 1.379 billion yuan in 2025, a year-on-year increase of 40.63%; net profit attributable to shareholders was 173 million yuan, a year-on-year increase of 416.37%.

Baiao Sai Tu stated that during the reporting period, the company’s growth in operating performance was mainly driven by the continuous expansion of overseas markets, combined with the recovery and rebound of the domestic biopharmaceutical industry. The company’s operating revenue achieved rapid growth. Additionally, the company adheres to a strategy of innovation-driven growth, building core technological barriers through sustained high-intensity R&D investment to ensure stable high gross margins. It also continuously improves operational efficiency through lean management, rapidly enhancing the company’s profitability.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.